{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidr4dnvtloqzffpxhpcp2ppl4q37jtvkafr4kj5m6xfluz6ioissy",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mkdzjcpto2z2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreidbhkd6nlm2gz2jty3zf4nilqzcmcdp4ylxbngueiukzhizixbffy"
    },
    "mimeType": "image/jpeg",
    "size": 504186
  },
  "path": "/news/2026-04-generation-kras-g12c-inhibitor-elisrasib.html",
  "publishedAt": "2026-04-25T16:30:02.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "Treatment with the investigational next-generation KRAS-G12C inhibitor elisrasib led to clinical benefit in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbored a KRAS G12C mutation and whose disease progressed after prior therapies, according to results presented at the American Association for Cancer Research (AACR) Annual Meeting 2026, held April 17-22.",
  "title": "Next-generation KRAS G12C inhibitor elisrasib elicited promising response rates in patients with advanced lung cancer"
}